BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/13/2015 10:26:00 AM | Browse: 1112 | Download: 1844
 |
Received |
|
2015-03-17 08:39 |
|
Peer-Review Started |
|
2015-03-24 20:18 |
|
To Make the First Decision |
|
2015-04-27 15:48 |
|
Return for Revision |
|
2015-04-28 18:32 |
|
Revised |
|
2015-05-09 00:00 |
|
Second Decision |
|
2015-05-25 12:04 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2015-06-02 17:39 |
|
Articles in Press |
|
|
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2015-09-25 16:18 |
|
Publish the Manuscript Online |
|
2015-10-13 10:26 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Randomized Controlled Trial |
| Article Title |
Randomized phase Ⅱ trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neck
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Michael Mix, Anurag K Singh, Michael Tills, Shiva Dibaj, Adrienne Groman, Wainwright Jaggernauth, Youcef Rustum and Michael B Jameson |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Health Research Council of New Zealand (In part) |
|
|
| Corresponding Author |
Anurag K Singh, MD, Professor of Medicine, Radiation Medicine Residency Program Director, University at Buffalo School of Medicine, Professor of Oncology, Director of Radiation Research, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, United States. anurag.singh@roswellpark.org |
| Key Words |
Selenium; Chemotherapy; Radiation therapy; Squamous cell cancer; Radioprotector; Chemoprotective |
| Core Tip |
This is an international, randomized, double-blind, placebo-controlled phase Ⅱ trial evaluating the addition of selenomethionine (SLM) to concurrent chemoradiation for locally advanced squamous cell carcinoma of the head and neck. The addition of SLM was well tolerated, but did not lead to a difference in the rates of mucositis, or quality of life outcomes vs placebo. |
| Publish Date |
2015-10-13 10:26 |
| Citation |
Mix M, Singh AK, Tills M, Dibaj S, Groman A, Jaggernauth W, Rustum Y, Jameson MB. Randomized phase Ⅱ trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neck. World J Clin Oncol 2015; 6(5): 166-173 |
| URL |
http://www.wjgnet.com/2218-4333/full/v6/i5/166.htm |
| DOI |
http://dx.doi.org/10.5306/wjco.v6.i5.166 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
